Global Diabetic Macular Edema (DME) Market Size to Exceed USD 8.64 Billion by 2035 | CAGR of 4.19%

Global Diabetic Macular Edema (DME) Market Size to Exceed USD 8.64 Billion by 2035

According to a Research Report Published by Decisions Advisors & Consulting, The Global Diabetic Macular Edema (DME) Market Size is expected to Grow from USD 5.50 Billion in 2024 to USD 8.64 Billion by 2035, at a CAGR of 4.19% during the forecast period 2025-2035.  

Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the "Global Diabetic Macular Edema (DME) Market Size, Share, and COVID-19 Impact Analysis, By Type (Focal Diabetic Macular Edema (DME), Diffuse Diabetic Macular Edema (DME)), By Drug Type (Ranibizumab (Lucentis), Aflibercept (Eylea), Dexamethasone (Ozurdex), Fluocinolone Acetonide (Iluvien), and Other Drugs), By Route of Administration (Intravitreal Injections, Intravitreal Implants, and Others), By Diagnosis (Fluorescein Angiography, Fundus Imaging, Optical Coherence Tomography (OCT), and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035."

Get Detailed Report Description Here: https://www.decisionsadvisors.com/reports/diabetic-macular-edema-dme-market 

The worldwide diabetic macular edema (DME) market targets the diagnosis, therapy, and management of DME, a significant vision-threatening issue associated with Type 2 diabetes due to fluid buildup in the macula of the retina. This market includes implants, medications, anti-VEGF intravitreal injections, sophisticated diagnostic instruments, and solutions for managing chronic diseases. The increasing worldwide incidence of diabetes and the related danger of vision impairment are leading to significant expansion in the DME market. Heightened awareness of diabetic eye diseases and early screening programs are driving the need for effective treatment solutions. However, the market encounters various challenges, such as elevated treatment expenses, safety issues tied to corticosteroid implants, inadequate patient awareness, and regulatory barriers that hinder the approval and uptake of novel therapies.

The diffuse diabetic macular edema (DME) segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.       

Based on the type, the diabetic macular edema (DME) market is segmented into focal diabetic macular edema (DME), and diffuse diabetic macular edema (DME). Among these, the diffuse diabetic macular edema (DME) segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. This is due to the wide affected area; it is more prevalent than localised DME and often causes more severe visual impairment. It typically requires more intensive therapy than focal DME, and symptoms include difficulty reading, diminished colour perception, and decreased vision.

The ranibizumab (Lucentis) segment accounted for the largest share in 2024 and is anticipated to grow at a substantial CAGR during the forecast period.       

Based on the drug type, the diabetic macular edema (DME) market is divided into ranibizumab (Lucentis), aflibercept (Eylea), dexamethasone (Ozurdex), fluocinolone acetonide (Iluvien), and other drugs. Among these, the ranibizumab (Lucentis) segment accounted for the largest share in 2024 and is anticipated to grow at a substantial CAGR during the forecast period. Ranibizumab's high acceptance rate is a result of its well-established safety profile, strong clinical validation, and widespread ophthalmologist awareness.

The intravitreal injections segment dominated the market in 2024 and is anticipated to grow at a significant CAGR during the forecast period.       

Based on the route of administration, the diabetic macular edema (DME) market is differentiated into intravitreal injections, intravitreal implants, and others. Among these, the intravitreal injections segment domainted the market in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Intravitreal injections have two advantages that enhance safety and efficacy: high absorption and reduced systemic exposure. Additionally, the established clinical protocols for intravitreal injection and the growing expertise of ophthalmologists have led to an improvement in patient acceptance.

The optical coherence tomography (OCT) segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.       

Based on the diagnosis, the diabetic macular edema (DME) market is divided into fluorescein angiography, fundus imaging, optical coherence tomography (OCT), and others. Among these, the optical coherence tomography (OCT) segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. This is because of continuous technological advancements, AI integration, and its critical role in remote patient monitoring and personalised treatment planning; OCT is also the fastest-growing category.

Asia Pacific is expected to hold the majority share of the global diabetic macular edema (DME) market during the forecast period.       

Asia Pacific is expected to hold the majority share of the global diabetic macular edema (DME) market during the forecast period. The United States is expected to lead for the duration of the projection period, and the North America region's dominant position is mostly owing to its robust healthcare system and important market participants. The market's growth is further aided by the region's continuous research initiatives and use of gene therapy to make superior solutions accessible.

North America is anticipated to grow at the fastest pace in the global diabetic macular edema (DME) market during the forecast period. This is due to research investments and advanced healthcare systems; the treatments for diabetic macular edema (DME) are expanding rapidly, and recent findings suggest that funding support for DME is needed. Germany leads the regional market due to proactive clinical studies, cutting-edge treatments, and strong ophthalmology networks.

Major vendors in the global diabetic macular edema (DME) market are Alimera Sciences Inc., Arctic Vision, Allergan Plc, Bayer AG, Allergan Plc., F. Hoffmann-La Roche Ltd., Valeant Pharmaceuticals International, Inc. (Bausch & Lomb Inc.), KalVista Pharmaceuticals, Genentech, Novartis AG, Ocugen, Inc., Regeneron Pharmaceuticals, Inc., Clearside Biomedical, Daiichi Sankyo, Chugai Pharmaceutical Co., Ltd., Oxurion (fka ThromboGenics), and Others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development   

• In February 2025, the FDA approved Roche's Susvimo (ranibizumab injectable, 100 mg/mL) as the first and only continuous delivery medication for diabetic macular edema (DME), the major cause of diabetes-related blindness. This approval means that patients may require as few as two treatments each year, providing a significant alternative to frequent eye injections.

Market Segment  

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the diabetic macular edema (DME) market based on the below-mentioned segments:  

Global Diabetic Macular Edema (DME) Market, By Type

• Focal Diabetic Macular Edema (DME)
• Diffuse Diabetic Macular Edema (DME)

Global Diabetic Macular Edema (DME) Market, By Drug Type

• Ranibizumab (Lucentis)
• Aflibercept (Eylea)
• Dexamethasone (Ozurdex)
• Fluocinolone Acetonide (Iluvien)
• Other off-label drugs

Global Diabetic Macular Edema (DME) Market, By Route of Administration

• Intravitreal Injections
• Intravitreal Implants
• Others

Global Diabetic Macular Edema (DME) Market, By Diagnosis

• Fluorescein Angiography
• Fundus Imaging
• Optical Coherence Tomography (OCT)
• Others

Global Diabetic Macular Edema (DME) Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa